Augustine Asset Management Inc. Acquires New Shares in United Therapeutics Corporation $UTHR

Augustine Asset Management Inc. acquired a new stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) in the second quarter, Holdings Channel reports. The fund acquired 5,282 shares of the biotechnology company’s stock, valued at approximately $1,518,000.

Several other hedge funds and other institutional investors also recently modified their holdings of UTHR. Vaughan Nelson Investment Management L.P. acquired a new position in shares of United Therapeutics during the first quarter valued at $101,354,000. Nuveen LLC acquired a new position in United Therapeutics during the 1st quarter valued at about $83,533,000. Amundi boosted its stake in United Therapeutics by 198.8% during the 1st quarter. Amundi now owns 350,193 shares of the biotechnology company’s stock valued at $107,635,000 after purchasing an additional 232,988 shares during the period. GAMMA Investing LLC boosted its stake in United Therapeutics by 29,415.2% during the 1st quarter. GAMMA Investing LLC now owns 221,954 shares of the biotechnology company’s stock valued at $68,422,000 after purchasing an additional 221,202 shares during the period. Finally, Acadian Asset Management LLC boosted its position in shares of United Therapeutics by 1,657.8% during the first quarter. Acadian Asset Management LLC now owns 179,205 shares of the biotechnology company’s stock worth $55,217,000 after buying an additional 169,010 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Buying and Selling at United Therapeutics

In related news, Director Christopher Causey sold 1,000 shares of the stock in a transaction that occurred on Wednesday, September 24th. The shares were sold at an average price of $440.00, for a total transaction of $440,000.00. Following the completion of the sale, the director directly owned 4,865 shares of the company’s stock, valued at $2,140,600. This represents a 17.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Paul A. Mahon sold 11,000 shares of the stock in a transaction that occurred on Thursday, September 18th. The shares were sold at an average price of $406.17, for a total transaction of $4,467,870.00. Following the sale, the executive vice president directly owned 36,781 shares of the company’s stock, valued at approximately $14,939,338.77. This represents a 23.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 192,935 shares of company stock valued at $73,905,462. Corporate insiders own 10.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on UTHR. HC Wainwright boosted their price objective on United Therapeutics from $400.00 to $500.00 and gave the stock a “buy” rating in a research report on Friday, September 5th. Jefferies Financial Group boosted their price target on United Therapeutics from $432.00 to $564.00 and gave the stock a “buy” rating in a research report on Tuesday, September 2nd. Wells Fargo & Company boosted their price target on United Therapeutics from $295.00 to $414.00 and gave the stock an “equal weight” rating in a research report on Wednesday, September 3rd. Bank of America upped their price objective on shares of United Therapeutics from $314.00 to $463.00 and gave the stock a “neutral” rating in a report on Tuesday, September 2nd. Finally, JPMorgan Chase & Co. reduced their price objective on shares of United Therapeutics from $350.00 to $330.00 and set an “overweight” rating for the company in a report on Tuesday, July 8th. Ten equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $448.14.

United Therapeutics Stock Up 1.7%

Shares of United Therapeutics stock opened at $432.66 on Friday. The firm has a market cap of $19.52 billion, a price-to-earnings ratio of 16.89, a price-to-earnings-growth ratio of 6.48 and a beta of 0.62. The business has a fifty day simple moving average of $342.90 and a 200-day simple moving average of $314.73. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $442.01.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share for the quarter, missing analysts’ consensus estimates of $6.80 by ($0.39). United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The business had revenue of $798.60 million during the quarter, compared to analyst estimates of $802.13 million. During the same period in the previous year, the company posted $5.85 earnings per share. United Therapeutics’s revenue was up 11.7% compared to the same quarter last year. Analysts anticipate that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.